Anti-angiogenic treatment strategies for the therapy of endometriosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
ResultsGrowth factor inhibitors Endogenous angiogenesis inhibitors Fumagillin analogues Statins Cyclo-oxygenase (COX)-2 inhibitors Phytochemical compounds Immunomodulators Dopamine agonists Peroxisome proliferator-activated receptor (PPAR) agonists Progestins, danazol and gonadotropin-releasing hormone (GnRH) agonists Other agents † Potential impact of anti-angiogenic treatment in future endometriosis therapy † Conclusionsbackground: Angiogenesis, i.e. the development of new blood vessels from pre-existing ones, represents an integral part in the pathogenesis of endometriosis.During the last decade, an increasing number of studies have therefore focused on the anti-angiogenic treatment of the disease.The present review provides a systematic overview of these studies and critically discusses the future role of anti-angiogenic therapy in the multimodal management of endometriosis.methods: Literature searches were performed in PubMed, MEDLINE and ISI Web of Knowledge for original articles published before the end of March 2012, written in the English language and focusing on anti-angiogenic approaches for the therapy of endometriosis.The searches included both animal and human studies.results: Numerous compounds of different substance groups have been shown to exert anti-angiogenic effects on endometriotic lesions under experimental in vitro and in vivo conditions.These include growth factor inhibitors, endogenous angiogenesis inhibitors, fumagillin analogues, statins, cyclo-oxygenase-2 inhibitors, phytochemical compounds, immunomodulators, dopamine agonists, peroxisome proliferator-activated receptor agonists, progestins, danazol and gonadotropin-releasing hormone (GnRH) agonists.However, clinical evidence for their efficacy in anti-angiogenic endometriosis therapy is still lacking.conclusions: Anti-angiogenic compounds hold great promise for the future treatment of endometriosis because they may inhibit the establishment of new endometriotic lesions in early stages of the disease or after surgical treatment.Further experimental studies, controlled clinical trials in particular, are required now to clarify which compounds fulfil these expectations without inducing severe side effects in patients with endometriosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 1×
“One of these key processes is angiogenesis, i.e. the development of new blood vessels from the pre-existing ones (Carmeliet and Jain, 2011).”
BackgroundHypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 2×
“The most potent stimulus for the up-regulation of VEGF is hypoxia (Shweiki et al., 1992), which prevents the intracellular degradation of ubiquitously expressed hypoxia-inducible factor-1a (HIF-1a; Harris, 2002).”
BackgroundEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 3×
“However, this clinical trial was not continued because rosiglitazone was shown to cause an increased risk of cardiovascular side effects (Nissen and Wolski, 2007).”
BackgroundInfluentialVascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“This 20–22 kDa C-terminal fragment of type XVIII collagen, which was originally isolated and purified from conditioned media of murine hemangioendothelioma cells (O’Reilly et al., 1997), binds to aVb1 integrin and E-selectin on endothelial cells and is a broad spectrum angiogenesis inhibitor, affecting hundreds of pat…”
BackgroundGiudice, L. C., & Kao, L. C. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17403-5 · Cited by 3,166
Tyagi, S., Gupta, P., Saini, A., Kaushal, C., & Sharma, S. (2011) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/2231-4040.90879 · Cited by 1,017
Recurrence of endometriosis and its control
Guo, S.-W. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp007 · Cited by 719
Angiopoietins: a link between angiogenesis and inflammation
Fiedler, U., & Augustin, H. G. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.10.004 · Cited by 606
Vascular endothelial growth factor (VEGF) in endometriosis
Donnez, J., Smoes, P., Gillerot, S., Casanas-Roux, F., & Nisolle, M. (1998) · Human Reproduction · doi:10.1093/humrep/13.6.1686 · Cited by 531 · cited 1×
“Of interest, highly active red endometriotic lesions contain the highest VEGF concentrations when compared with other lesion types (Donnez et al., 1998).”
BackgroundChronic pelvic pain and endometriosis: translational evidence of the relationship and implications
Stratton, P., & Berkley, K. J. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmq050 · Cited by 442 · cited 1×
“Although some affected women may remain asymptomatic, endometriosis is typically associated with a wide spectrum of pain symptoms (Stratton and Berkley, 2011) and infertility (Garrido et al., 2002; Bulletti et al., 2010).”
BackgroundEndometriosis: cost estimates and methodological perspective
Simoens, S., Hummelshoj, L., & D'Hooghe, T. (2007) · Human Reproduction Update · doi:10.1093/humupd/dmm010 · Cited by 357
Vascular endothelial growth factor and endometriotic angiogenesis
McLaren, J. (2000) · Human Reproduction Update · doi:10.1093/humupd/6.1.45 · Cited by 269 · cited 1×
“Accordingly , early developing lesions, which are the most active ones, have a typically pink-red appearance because of their high vascular density (McLaren, 2000; Laschke et al., 2011a; Fig.”
BackgroundEndogenous inhibitors of angiogenesis
Ribatti, D. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.11.019 · Cited by 191 · cited 3×
“Another endogenous inhibitor of angiogenesis is angiostatin, which is a 38 kDa fragment of plasminogen (O'Reilly et al., 1994; Ribatti, 2009).”
BackgroundAngiongenesis: a new theory for endometriosis
Healy, D. (1998) · Human Reproduction Update · doi:10.1093/humupd/4.5.736 · Cited by 173 · cited 1×
“Based on these findings, endometriosis has been classified as a typical angiogenic disease, such as cancer, psoriasis or diabetic retinopathy (Healy et al., 1998).”
BackgroundVasculogenesis: A new piece of the endometriosis puzzle
Laschke, M. W., Giebels, C., & Menger, M. D. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmr023 · Cited by 136
Self-citationLearning to take charge: women's experiences of living with endometriosis
Cox, H., Henderson, L., Wood, R., & Cagliarini, G. (2003) · Complementary Therapies in Nursing and Midwifery · doi:10.1016/s1353-6117(02)00138-5 · Cited by 104 · cited 1×
“Among women with endometriosis, Chinese herbal medicine has gained popularity as alternative pain therapy despite the lack of conclusive clinical evidence (Cox et al., 2003; Wieser et al., 2007).”
BackgroundCirculating Endothelial Progenitor Cells Are Up-Regulated in a Mouse Model of Endometriosis
Becker, C. M., Beaudry, P., Funakoshi, T., Benny, O., Zaslavsky, A., Zurakowski, D., Folkman, J., D'Amato, R. J., & Ryeom, S. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2010.12.037 · Cited by 81 · cited 4×
“, 2006b) Lodamin See TNP-470 No reported treatment-related side effects (E) (Benny et al., 2008; Becker et al., 2011)”
BackgroundInfluentialOzawa, Y., Murakami, T., Tamura, M., Terada, Y., Yaegashi, N., & Okamura, K. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.01.057 · Cited by 76 · cited 2×
“treatment with COX-2 inhibitors prevents the implantation of endometrium to ectopic sites and induces the regression of established endometriotic lesions (Dogan et al., 2004; Matsuzaki et al., 2004b; Ozawa et al., 2006; Machado et al., 2010; Olivares et al., 2011).”
BackgroundEvolution of medical treatment for endometriosis: back to the roots?
Wieser, F., Cohen, M., Gaeddert, A., Yu, J., Burks-Wicks, C., Berga, S. L., & Taylor, R. N. (2007) · Human Reproduction Update · doi:10.1093/humupd/dmm015 · Cited by 76
The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis
Olivares, C., Ricci, A., Bilotas, M., Barañao, R. I., & Meresman, G. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.05.063 · Cited by 65
Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis
Nakamura, M., Katsuki, Y., Shibutani, Y., & Oikawa, T. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00765-7 · Cited by 63 · cited 1×
“Dienogest, an orally active progestin with a favourable safety and tolerability profile, has been shown to inhibit both embryonic and tumour cell-induced angiogenesis (Nakamura et al., 1999).”
BackgroundBouhlel, M. A., Staels, B., & Chinetti‐Gbaguidi, G. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01892.x · Cited by 51 · cited 2×
“…et al., 2011) Increase of plasma creatinine and homocysteine levels, myopathy, thrombosis, pulmonary embolism, pancreatitis (C) (Keech et al., 2005; Bouhlel et al., 2008) Rosiglitazone Binding to PPAR-g Pleiotropic action on multiple processes including energy homeostasis, metabolism, inflammation…”
BackgroundPullen, N., Birch, C. L., Douglas, G. J., Hussain, Q., Pruimboom-Brees, I., & Walley, R. J. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmr030 · Cited by 42
Cited by
Consensus on current management of endometriosis
Johnson, N. P., Hummelshoj, L., for the World Endometriosis Society Montpellier Consortium, Abrao, M. S., Adamson, G. D., Allaire, C., Amelung, V., Andersson, E., Becker, C., Birna Árdal, K. B., et al. (2013) · Human Reproduction · doi:10.1093/humrep/det050 · Cited by 558
Pathogenesis of endometriosis: The genetic/epigenetic theory
Koninckx, P. R., Ussia, A., Adamyan, L., Wattiez, A., Gomel, V., & Martin, D. C. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.10.013 · Cited by 427
Treatment of pelvic pain associated with endometriosis: a committee opinion
(2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.02.012 · Cited by 397
Pathogenesis of deep endometriosis
Gordts, S., Koninckx, P., & Brosens, I. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.08.036 · Cited by 241
Peripheral changes in endometriosis-associated pain
Morotti, M., Vincent, K., Brawn, J., Zondervan, K. T., & Becker, C. M. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu021 · Cited by 198
Metadata
- Authors
- Laschke, M. W., & Menger, M. D.
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-06-19
- Volume
- 18
- Issue
- 6
- Pages
- 682-702
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2111141200
- Cited by
- 153
- References
- 26
- FWCI
- 14.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.